My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Ionis Pharmaceuticals, Inc. - Common Stock (NQ:IONS)

80.82 +1.68 (+2.12%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 12, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ionis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 ↗

October 31, 2024

The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings.

Via Benzinga

Topics ETFs Stocks

Avidity Biosciences, Up 441%, Nears Another Record High As Dystrophy Space Heats Up ↗

October 18, 2024

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

Via Investor's Business Daily

New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA

October 08, 2024

From Biogen Inc.

Via GlobeNewswire

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (13 Ratings) ↗

September 26, 2024

Via Benzinga

What 14 Analyst Ratings Have To Say About Ionis Pharmaceuticals ↗

August 26, 2024

Via Benzinga

Rubrik Reports Q2 Results, Joins Ionis Pharmaceuticals, Hewlett Packard Enterprise And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

September 10, 2024

Via Benzinga

Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket ↗

September 10, 2024

Via Benzinga

Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations

September 04, 2024

From Praxis Precision Medicines, Inc.

Via GlobeNewswire

12 Analysts Have This To Say About Ionis Pharmaceuticals ↗

August 02, 2024

Via Benzinga

The Latest Analyst Ratings For Ionis Pharmaceuticals ↗

July 16, 2024

Via Benzinga

Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts ↗

June 27, 2024

Via Benzinga

Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA

September 04, 2024

From Biogen Inc.

Via GlobeNewswire

Ionis' Rare Development Disorder Drug Candidate 'Could Be Differentiated' From Peer Ultragenyx: Analyst ↗

July 22, 2024

Ionis Pharmaceuticals releases positive results from Phase 1/2 study of ION582 for Angelman syndrome, showing consistent clinical improvements in communication, cognition, and motor function. Safety...

Via Benzinga

Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong ↗

July 22, 2024

Biogen previously decided against opting into Ionis' Angelman program.

Via Investor's Business Daily

RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

June 24, 2024

Via Benzinga

Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) ↗

June 03, 2024

Via Benzinga

The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals ↗

May 08, 2024

Via Benzinga

Masters In Trading - Saturday, June 22 ↗

June 22, 2024

In this video, I discuss a stock that is expected to see major upside, and I take a closer look at my portfolio.

Via Talk Markets

Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile ↗

May 31, 2024

Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application submission expected this year.

Via Benzinga

Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder ↗

May 31, 2024

The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-approved treatment targeting the genetic cause of ALS.

Via Benzinga

Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another ↗

May 16, 2024

Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on key clinical outcomes.

Via Benzinga

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

May 16, 2024

From Biogen Inc.

Via GlobeNewswire

The Latest Analyst Ratings For Ionis Pharmaceuticals ↗

April 09, 2024

Via Benzinga

The 3 Most Undervalued Pharma Stocks to Buy in May 2024 ↗

May 09, 2024

Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.

Via InvestorPlace

IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

IONS stock results show that Ionis Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

Via InvestorPlace

Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows ↗

March 13, 2024

Ionis Pharmaceuticals reports positive Phase 2 results for ION224, showing significant improvement in MASH and liver histology without worsening fibrosis. Safe and well-tolerated treatment with...

Via Benzinga

Are These 5 Undervalued Stocks Ready to Break Out?

March 08, 2024

Undervalued stocks Albemarle, Ionis, Insulet, Hess and Wynn beat earnings views, offering potential for investors to buy quality companies at discounted prices.

Via MarketBeat

New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy

March 06, 2024

From Biogen Inc.

Via GlobeNewswire

Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals ↗

February 22, 2024

Via Benzinga

Earnings Scheduled For February 21, 2024 ↗

February 21, 2024

Companies Reporting Before The Bell • Gatos Silver (NYSE:GATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.